Wave Life Sciences Future Growth
Future criteria checks 2/6
Wave Life Sciences is forecast to grow earnings and revenue by 38.1% and 42.4% per annum respectively. EPS is expected to grow by 42.8% per annum. Return on equity is forecast to be -78.2% in 3 years.
Key information
38.1%
Earnings growth rate
42.8%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 42.4% |
| Future return on equity | -78.2% |
| Analyst coverage | Good |
| Last updated | 10 Dec 2024 |
Recent future growth updates
Recent updates
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Nov 15
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Nov 09Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Oct 16There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Sep 25Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Sep 24Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Sep 08We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 116 | -122 | -176 | -147 | 8 |
| 12/31/2025 | 69 | -153 | -153 | -138 | 10 |
| 12/31/2024 | 51 | -153 | -175 | -152 | 9 |
| 9/30/2024 | 54 | -143 | -142 | -141 | N/A |
| 6/30/2024 | 111 | -73 | -130 | -129 | N/A |
| 3/31/2024 | 113 | -62 | -139 | -138 | N/A |
| 12/31/2023 | 113 | -58 | -21 | -19 | N/A |
| 9/30/2023 | 85 | -85 | -21 | -20 | N/A |
| 6/30/2023 | 37 | -131 | -12 | -11 | N/A |
| 3/31/2023 | 15 | -151 | -4 | -2 | N/A |
| 12/31/2022 | 4 | -162 | -129 | -128 | N/A |
| 9/30/2022 | 4 | -153 | -103 | -101 | N/A |
| 6/30/2022 | 40 | -120 | -105 | -104 | N/A |
| 3/31/2022 | 43 | -118 | -85 | -84 | N/A |
| 12/31/2021 | 41 | -122 | -90 | -89 | N/A |
| 9/30/2021 | 49 | -116 | -114 | -113 | N/A |
| 6/30/2021 | 16 | -143 | -106 | -105 | N/A |
| 3/31/2021 | 16 | -145 | -135 | -134 | N/A |
| 12/31/2020 | 20 | -150 | -117 | -116 | N/A |
| 9/30/2020 | 13 | -178 | -148 | -146 | N/A |
| 6/30/2020 | 13 | -196 | -172 | -169 | N/A |
| 3/31/2020 | 17 | -197 | -168 | -164 | N/A |
| 12/31/2019 | 16 | -194 | -192 | -188 | N/A |
| 9/30/2019 | 17 | -175 | -166 | -160 | N/A |
| 6/30/2019 | 19 | -162 | -154 | -145 | N/A |
| 3/31/2019 | 16 | -156 | -50 | -41 | N/A |
| 12/31/2018 | 14 | -147 | -33 | -23 | N/A |
| 9/30/2018 | 12 | -140 | -23 | -13 | N/A |
| 6/30/2018 | 9 | -127 | N/A | -7 | N/A |
| 3/31/2018 | 5 | -116 | N/A | -99 | N/A |
| 12/31/2017 | 4 | -102 | N/A | -84 | N/A |
| 9/30/2017 | 3 | -90 | N/A | -74 | N/A |
| 6/30/2017 | 3 | -82 | N/A | -63 | N/A |
| 3/31/2017 | 2 | -69 | N/A | -42 | N/A |
| 12/31/2016 | 1 | -56 | N/A | -32 | N/A |
| 9/30/2016 | 1 | -44 | N/A | -25 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -16 | N/A |
| 3/31/2016 | 0 | -24 | N/A | -18 | N/A |
| 12/31/2015 | 0 | -19 | N/A | -13 | N/A |
| 9/30/2015 | 0 | -14 | N/A | -7 | N/A |
| 6/30/2015 | 0 | -10 | N/A | -5 | N/A |
| 3/31/2015 | 0 | -8 | N/A | -5 | N/A |
| 12/31/2014 | N/A | -5 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WVE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: WVE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: WVE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: WVE's revenue (42.4% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: WVE's revenue (42.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WVE is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wave Life Sciences Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Steven Seedhouse | CGS International |
| Whitney Ijem | Guggenheim Securities, LLC |